Memoniq (Piracetam)

Piracetam influences neuronal membrane fluidity and enhances the activity of acetylcholine and glutamate receptors. By facilitating calcium influx and improving cerebral blood flow, it promotes neuroplasticity and more efficient synaptic transmission, which together support cognitive and motor functions.

The appropriate dose of Memoniq is determined by the prescribing clinician based on the individual’s medical condition, age, renal and hepatic function, and response to therapy. Specific dosing regimens are not disclosed publicly and should be obtained from a qualified health professional.

Safety data for Piracetam in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually.

To order Memoniq, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memoniq (Piracetam) belongs to the racetam class, which differs from stimulant‑based nootropics by acting on membrane fluidity and neurovascular function rather than directly increasing catecholamine levels. Compared with other racetams, Piracetam has a well‑established safety profile but may be less potent than newer analogues such as Aniracetam or Oxiracetam.

Memoniq should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Memoniq is administered orally. The tablet (or other oral form) should be swallowed whole with a glass of water, preferably with or after a meal to reduce gastrointestinal discomfort. Patients should follow the instructions provided by their healthcare professional.

Serious, though rare, risks associated with Memoniq include allergic reactions such as rash, angioedema, or anaphylaxis, hematological abnormalities like thrombocytopenia, and psychiatric symptoms including agitation or depression. Any of these events should prompt immediate medical evaluation.

Memoniq is contraindicated in individuals with known hypersensitivity to Piracetam or any excipients in the formulation. Caution is advised for patients with severe renal or hepatic impairment, and it should be avoided in those taking anticoagulants without close monitoring.